| |
Integrated digital solutions are essential to the success of modern trials. Discover how IQVIA led a unified delivery team to streamline operations and implement a purpose-built, integrated IRT and Complete Consent solution. Download the case study!
|
|
|
Wednesday, June 4, 2025 | 1pm ET / 10am PT When it comes to connecting with HCPs, data is key. Physician-Level Data (PLD), is the MVP of insights, delivering the more granular information you need to easily see what’s working, what’s missing the mark, and optimize your strategy in real time. Register now to learn how PLD can supercharge your HCP marketing game and gain practical tips for leveraging.
|
|
| By Nick Paul Taylor The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, which was aiming to report data in mid-2026, dropped its targeted trial completion date and outlined actions to extend its cash runway after suffering the setback. |
|
|
|
By Kevin Dunleavy After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers in the first three months of 2025. In the first quarter, seven large pharma companies saw their revenue decrease year over year, all from the United States. |
By Gabrielle Masson Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion acquisition of Chinook, including a former director of the biotech’s board. |
By Zoey Becker The layoffs at Allergan's Irvine, California, headquarters are effective on July 22, according to a recent filing with the state. |
|
Thursday, June 5, 2025 | 11am ET / 8am PT Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now.
|
|
By Darren Incorvaia An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of CRISPR on human embryos. |
By Fraiser Kansteiner In the ASCENT-03 trial, Gilead's Trodelvy bested chemotherapy at extending the time before disease worsening or death in certain patients with previously untreated metastatic triple-negative breast cancer. The results help pad the case for Trodelvy in first-line breast cancer following positive results for a Trodelvy-Keytruda cocktail in a similar indication last month. |
By Nick Paul Taylor Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” |
By Nick Paul Taylor Sanofi’s sponsorship of the Olympics and Paralympics has led to a breach of the U.K. marketing code. Self-regulatory body the PMCPA ruled that the company brought discredit on the pharma industry by giving 21 tickets to the games, worth a combined 2,190 euros ($2,488), to patients in the U.K. |
By Conor Hale Roche tapped a subsidiary of the MIT and Harvard research center to apply sequencing-by-expansion tech in screening newborns and their parents. |
By Fraiser Kansteiner The FDA has slapped Savara with a refuse to file letter after the biotech in March applied for approval of its inhaled respiratory disease candidate molgramostim in autoimmune pulmonary alveolar proteinosis. |
Fierce podcastsDon’t miss an episode |
| | Though some mental health patients need referrals to higher levels of care, the process is often inefficient and risks patients dropping out of treatment. Grow Therapy's new care coordination program aims to prevent that. |
|
|---|
|
|
|
Regulatory demands and unpredictable market forces are reshaping the life sciences landscape. It is crucial for organizations to embrace digital validation for improving efficiency, consistency, and compliance. Access this valuable and timely guide to learn more. Discover how digitizing validation can help reduce costs, shorten timelines, and enhance traceability.
|
|
| WhitepaperExplore how NLP and generative AI, including models like ChatGPT, are transforming precision medicine and life sciences. Sponsored by: IMO Health |
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
